Clinical Trials Logo

Filter by:
NCT ID: NCT06088290 Recruiting - Leiomyosarcoma Clinical Trials

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma

SaLuDo
Start date: September 21, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of this phase IIb/III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when compared to doxorubicin administered as a single agent.

NCT ID: NCT06088264 Completed - Clinical trials for Healthy Male Participants

A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants

Start date: October 31, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the drug levels, metabolism, and removal of BMS-986322 in healthy adult male participants.

NCT ID: NCT06088251 Completed - Chronic Disease Clinical Trials

Evaluation of Nutrition Training Augmented With Digital Technology in Graduate Medical Education

Start date: October 24, 2023
Phase: N/A
Study type: Interventional

Investigators will conduct a randomized controlled evaluation of standard nutrition education vs. standard education + Nutri, and interactive clinical software that automates diet assessment and guides resident physicians through personalized and evidence-based diet counseling. Investigators will evaluate differences in resident-reported diet counseling competence and self-efficacy using survey measures. Investigators will evaluate skills using a simulated patient appointment and coding scheme described in prior work.

NCT ID: NCT06088199 Recruiting - Plaque Psoriasis Clinical Trials

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

Start date: October 24, 2023
Phase: Phase 3
Study type: Interventional

The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.

NCT ID: NCT06088043 Recruiting - Plaque Psoriasis Clinical Trials

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Start date: November 6, 2023
Phase: Phase 3
Study type: Interventional

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 56 weeks.

NCT ID: NCT06087991 Recruiting - Opioid Abuse Clinical Trials

Buprenorphine Induction and Naloxone Distribution Program-Combined With Warm Hand-Off Referral to Continued Treatment

BINDeR-TX
Start date: April 1, 2023
Phase:
Study type: Observational

This study is a collaboration between the University of Utah and Castleview Hospital in Price, Utah. Buprenorphine is a medication approved by the FDA to treat Opioid Use Disorder (OUD). Castleview Hospital currently does not prescribe buprenorphine in the emergency department (ED) instead it refers patients to outside addiction treatment facilities. This is a service focused project which the University of Utah will provide mentoring and education to Castleview in implementing an in ED buprenorphine/naloxone distribution program along with referral to continued services. After the program has been implemented, the investigators will evaluate it using quantitative surveys of program participants and qualitative interviews of hospital staff and stakeholders.

NCT ID: NCT06087978 Completed - Clinical trials for Healthy Male Subjects

Study of RPT193 in Healthy Adult Male Subjects

Start date: July 5, 2023
Phase: Phase 1
Study type: Interventional

Phase 1, open-label, absorption, metabolism, excretion, and mass balance study.

NCT ID: NCT06087926 Recruiting - Parkinson Disease Clinical Trials

Apathy in Parkinson Disease TMS Study

PDTMSAPATHY
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to develop non-invasive brain stimulation targets for the treatment of apathy, or motivation problems, in Parkinson Disease. The main questions the study aims to answer are: 1. Does transcranial magnetic stimulation change effort task performance in Parkinson's Disease patients? 2. Is there a link between brain signals and apathy? Participants will - complete questionnaires and assessments - perform an effort task - have their brain activity recorded (EEG) - receive non-invasive brain stimulation (TMS) Researchers will compare two stimulation locations (experimental site and control site) to see if TMS of the experimental site has an effect on apathy. Participants will receive stimulation of both sites (during separate visits).

NCT ID: NCT06087913 Recruiting - Safety Issues Clinical Trials

Safety and PK Multi-dose Study of TAF/EVG Vaginal Insert

Start date: November 8, 2023
Phase: Phase 1
Study type: Interventional

MATRIX-001 will examine the safety, PK, modeled PD, and acceptability of inserts containing the combination of TAF and EVG applied vaginally, daily for 3 days, then every other day for 14 days. The inserts are ultimately intended to be the basis of an event-driven, on-demand method for prevention of HIV and HSV sexual infection.

NCT ID: NCT06087861 Recruiting - Soft Tissue Sarcoma Clinical Trials

5-Day Preoperative Radiation for Soft Tissue Sarcoma

Start date: October 6, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine the safety and efficacy of an abbreviated course of preoperative radiation, given over five days, for patients with soft tissue sarcoma of the extremity, trunk or retroperitoneum. This is in contrast to standard preoperative radiation, which is given over 25 days.